Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
MDCX Chart
Medicus Pharma eyes compassionate use approval of Skinject for Gorlin Syndrome - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's recent steps to expand compassionate access to Skinject, its lead non-invasive treatment for non-melanoma skin diseases. The initiative involves a partnership with the Gorlin Syndrome Alliance, aiming to address unmet needs for patients living with this rare genetic condition.
Medicus Pharma, Gorlin Syndrome Alliance partner to expand SKINJECT access
Medicus Pharma (NASDAQ:MDCX) has partnered with the Gorlin Syndrome Alliance (GSA) to expand compassionate access to its investigational microneedle therapy, SKINJECT, for patients suffering from Gorlin Syndrome, a rare genetic condition that causes recurring skin cancers. Under the collaboration, the two groups will pursue an Expanded Access Investigational New Drug (IND) program with the US Food and Drug Administration (FDA) to allow patients with multiple or inoperable basal cell carcinomas (BCCs) to receive SKINJECT under physician supervision.
Medicus Pharma CEO discusses latest skin cancer trial milestone - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's latest milestone in its ongoing Phase 2 clinical trial for a novel, noninvasive treatment for non-melanoma skin cancer. Bokhari shared that Medicus Pharma has now treated its first patient outside the United States, at the Cleveland Clinic Abu Dhabi, expanding the study into an international trial.
Medicus Pharma Ltd (MDCX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Medicus Pharma Ltd ever had a stock split?
Medicus Pharma Ltd Profile
| Biotechnology Industry | Healthcare Sector | Raza Bokhari MBA CEO | NASDAQ (CM) Exchange | CA58471K2020 ISIN |
| CA Country | 12 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Medicus Pharma Ltd stands out as a leading entity in the pharmaceutical industry, concentrated on the research, development, and bringing to market innovative health care solutions. The core mission of the firm is to cater to unmet medical needs through the creation of a diversified portfolio of therapeutic treatments, concentrating primarily on areas such as oncology, neurology, and immunology. With a heavy reliance on biotechnology and avant-garde medical research, Medicus Pharma Ltd is firmly positioned as a significant figure in the life sciences domain. The organization is deeply committed to enhancing the quality and efficacy of treatments, thereby contributing significantly to the elevation of global healthcare standards. Beyond its influence on the pharmaceutical landscape, Medicus Pharma Ltd is instrumental in enhancing the health and well-being of patients and healthcare systems worldwide. As a frontrunner in the market, it engages in collaborations with academic bodies and industry counterparts, aiming to stimulate innovation and hasten the delivery of potentially life-saving drugs.
Products and Services
The range of products and services offered by Medicus Pharma Ltd is extensive, with each category tailored to address specific healthcare challenges:
- Oncology Treatments: Medicus Pharma Ltd develops innovative therapies aimed at treating various forms of cancer. These treatments focus on improving patient outcomes and include targeted therapy, immunotherapy, and traditional chemotherapy. By leveraging the latest research in oncology, the company strives to offer more effective and less toxic options to patients.
- Neurology Solutions: In the realm of neurology, the company is dedicated to discovering treatments for neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Through cutting-edge research, Medicus Pharma Ltd aims to provide patients with treatments that can alleviate symptoms, halt disease progression, and improve quality of life.
- Immunology Therapies: Focusing on disorders of the immune system such as autoimmune diseases, Medicus Pharma Ltd is at the forefront of developing therapies that modulate the immune response. These treatments are designed to target underlying causes of immune-related conditions, offering new hope to patients suffering from diseases like rheumatoid arthritis, lupus, and inflammatory bowel disease.
Each product and service provided by Medicus Pharma Ltd encapsulates the company's commitment to pioneering healthcare advancements, ensuring that their offerings not only meet the highest standards of safety and effectiveness but also address the evolving needs of patients and healthcare professionals around the globe.
Contact Information
